CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 110 enrolled
Drug / intervention
Nivolumab +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03004833
NCT03004833Phase 2Completed
CompareCT.gov

Nivolumab and AVD in Early-stage Unfavorable Classical Hodgkin Lymphoma

University of Cologne·interventional·Posted Dec 29, 2016·Updated Apr 3, 2025

In Brief

A Phase 2 clinical trial evaluating Nivolumab, Adriamycin, and 2 other interventions for Classical Hodgkin Lymphoma. Completed, enrolled 110 participants across 1 site.

Detailed Summary

The aim of the trial is to improve first-line treatment for early unfavorable cHL by introduction of the anti-PD-1 antibody Nivolumab with a truncated standard chemotherapy (AVD). The primary objective is to show efficacy of the two experimental treatment strategies. Secondary objectives are to further evaluate efficacy, show safety and feasibility and perform correlative studies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsClassical Hodgkin Lymphoma
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedDec 29, 2016
Enrollment StartFeb 21, 2017
Primary CompletionAug 22, 2022
TodayJul 2, 2026
Enrollment to primary: 5.5 yearsPosted 9.5 years ago

Interventions

Nivolumabdrug

Infusion of Nivolumab

Adriamycindrug

Infusion of Adriamycin

Vinblastinedrug

Infusion of Vinblastine

Dacarbazinedrug

Infusion of Dacarbazine